Valuation: ExpreS2ion Biotech Holding AB

Market Cap 24.7M 2.49M 2.23M 2.07M 1.87M 3.5M 237M 3.54M 9.84M 124M 9.35M 9.15M 394M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 24.7M 2.49M 2.23M 2.07M 1.87M 3.5M 237M 3.54M 9.84M 124M 9.35M 9.15M 394M EV / Sales 2026 *
0.81x
EV / Sales 2027 * -
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -
1 day-0.96%
1 week-2.83%
Current month-13.45%
1 month-7.62%
3 months-26.43%
6 months-53.60%
Current year-93.52%
1 week 0.9
Extreme 0.9
1.1
1 month 0.88
Extreme 0.88
1.2
Current year 0.88
Extreme 0.88
17.76
1 year 0.88
Extreme 0.88
19.54
3 years 0.88
Extreme 0.88
232
5 years 0.88
Extreme 0.88
2,352
10 years 0.88
Extreme 0.88
2,760
Manager TitleAgeSince
Chief Executive Officer - 2019-12-19
Director of Finance/CFO 50 2020-09-30
Chief Tech/Sci/R&D Officer - 2019-12-31
Director TitleAgeSince
Chairman 66 2009-12-31
Director/Board Member 58 2017-03-31
Director/Board Member 69 2021-05-25
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/22 Sell

Chief Technology Officer

12,000 0.0322%
9/19/22 Exercice

Chief Technology Officer

10,000 0.0268%
9/14/22 Exercice 55,589 0.1490%
Change 5-day change 1-year change 3-year change Capi.($)
-0.96%-2.83%-94.05%-97.31% 2.49M
+0.90%+1.85%+57.82%+128.79% 1,143B
+0.97%+5.24%+45.13%+84.51% 647B
-0.05%+0.67%+26.00%+102.06% 506B
-0.05%+1.73%+52.74%+65.27% 384B
-0.74%-6.18%+61.58%+36.95% 350B
+0.34%+1.84%+30.70%+52.69% 293B
-0.45%+1.19%+2.89%+24.92% 265B
+0.87%+2.77%+54.22%+71.16% 242B
+0.21%+3.54%+34.89%+104.46% 197B
Average +0.15%+0.57%+27.19%+57.35% 402.75B
Weighted average by Cap. +0.46%+0.71%+44.70%+87.25%

Financials

2026 *2027 *
Net sales 30.4M 3.07M 2.75M 2.54M 2.3M 4.3M 292M 4.35M 12.11M 153M 11.5M 11.26M 485M -
Net income - -
Net Debt - -
Projected Income Statement - Annual - ExpreS2ion Biotech Holding AB
Logo ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
Employees
19
Date Price Change Volume
26-10-28 SEK 1.030 -0.96% 20,299
26-10-27 SEK 1.040 +5.05% 77,809
26-10-26 SEK 0.9900 -5.71% 307,308
26-10-23 SEK 1.050 -2.78% 264,441
26-10-22 SEK 1.080 +1.89% 46,533

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ExpreS2ion Biotech Holding AB
  1. Stock Market
  2. Stocks
  3. EXPRS2 Stock